Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets

被引：0
作者：
Cho, William C. S. [1 ]
Roukos, Dimitrios H. [2 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] GenNetMed Ioannina Univ, Ctr Biosyst & Genom Network Med CBS, Ioannina, Greece
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
breast cancer; drugs; genome; HER2-positive; trastuzumab; trastuzumab emtansine; NEXT-GENERATION; PHASE-II; ARCHITECTURE; LAPATINIB; PLUS;
D O I：
10.1586/ERA.12.152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 8
页数：4
相关论文
共 50 条
  • [21] Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
    Krop, Ian
    Winer, Eric P.
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 15 - 20
  • [22] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    Tsang, R. Y.
    Finn, R. S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
  • [23] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [24] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Dhillon, Sohita
    DRUGS, 2014, 74 (06) : 675 - 686
  • [25] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Sohita Dhillon
    Drugs, 2014, 74 : 675 - 686
  • [26] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
  • [27] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
  • [28] Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
    T Waddell
    A Kotsori
    A Constantinidou
    N Yousaf
    S Ashley
    M Parton
    M Allen
    N Starling
    P Papadopoulos
    M O'Brien
    I Smith
    S Johnston
    British Journal of Cancer, 2011, 104 : 1675 - 1679
  • [29] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Negar Pourjamal
    Narjes Yazdi
    Aleksi Halme
    Vadim Le Joncour
    Pirjo Laakkonen
    Pipsa Saharinen
    Heikki Joensuu
    Mark Barok
    Clinical & Experimental Metastasis, 2024, 41 : 91 - 102
12345